LAUSR

During the initial peak of the 2019 coronavirus pandemic, a group of researchers in England reported a cohort of children with hyperinflammatory shock and cardiac features reminiscent of Kawasaki disease or toxic shock syndrome. The children developed symptoms 2–4 weeks after acute clinical and serologic evidence of coronavirus disease of 2019 (COVID-19) infection. By May, the Centers for Disease Control and Prevention (CDC) published an online Health Advisory that summarized the manifestations of reported multisystem inflammatory syndrome in children (MIS-C). Children with this syndrome have been recognized worldwide and case definitions between the CDC, the World Health Organization, and the Royal College of Paediatrics and Child Health (RCPCH) have been similar, considering the pace of evaluation in this newly recognized disease. While the acronym MIS-C remains in use, the RCPCH and many others use “pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2” (PIMS-TS). Fever and nonspecific symptoms, including vomiting, abdominal pain, and diarrhea, have been the most common presenting symptoms of PIMS-TS, with rash and conjunctival injection occurring in about half of children. Some patients have presented with shock, and sepsis must be excluded early in management. While multisystem involvement is required for the diagnosis, cardiac features have been a prominent concern during the acute phase of PIMS-TS. Reduced ejection fraction and pericardial effusion have been the most common echocardiographic features and cardiac inflammatory markers, including troponin I and creatinine kinase subsets, have been elevated. Shortly after the description of PIMS-TS, case series began to appear with retrospective evaluations from single centers. In some of these, cardiac involvement was reported in 100% of patients with PIMS-TS, although most noted that this was not a uniform complication. Reports varied about whether there was full resolution after discharge or whether cardiac features persisted (Table 1). In this issue of JMRI, Bartoszek et al report a retrospective study of 19 children, hospitalized for PIMS-TS between November 2020 and January 2021. Unlike other studies, the authors described a cohort who had definitive cardiac involvement during PIMS-TS, as determined by either decreased left ventricular ejection fraction (<55% in 18 of 19 patients) or elevation in troponin I serum biomarkers. Patients underwent cardiac magnetic resonance imaging (MRI) with myocardial tissue characterization 90–100 days after the diagnosis. All patients had normal dark blood T2 imaging, normal T1/ T2/extracellular volume mapping values, and no late gadolinium enhancement. Small pericardial effusion was noted in three patients (16%). These findings are similar to a recent prospective study, also on a small number of children, that similarly demonstrated no cardiac abnormalities by MRI during mid-term follow-up. Clinicians are left with the difficulty of reconciling some reports that have shown myocardial scarring after PIMS-TS and even one larger survey-based study that reported late gadolinium enhancement on cardiac MRI in 14% of patients with these newer data that show fewer or no long-term complications. When balancing the utility of post-hospitalization cardiac MRI and the potential risks of repeated gadoliniumbased contrast exposure, we must bear in mind that early reports of new disease states tend to overrepresent severe findings. The presence of severe disease is part of what allows a new entity to be distinguished from the usual variation in existing clinical entities. This occurred early in PIMS-TS as clinicians realized that children were not presenting with sepsis or unrelated disease, but with a postinfectious inflammatory condition related to SARS-CoV-2 (severe acute